A new class of weight-loss drug just took a major step toward approval for use. In a phase 3 clinical trial, the medication retatrutide helped control blood sugar levels in participants with type 2 ...

The two Phase 3 readouts Lilly has disclosed so far signal that retatrutide might be even more powerful than tirzepatide, the medicine the company sells as Zepbound for obesity and Mounjaro for ...

The Vikings’ second half was one of the most feeble, noncompetitive, embarrassing performances this writer has witnessed in an NFL game.

400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE)-- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...

400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...

Abstract: This paper presents a model-free predictive current control (MFPCC) strategy for dual three-phase permanent magnet synchronous motor (DTP-PMSM) drives that specifically aims to minimize ...

Bitcoin (BTC) price could be entering its most frustrating phase of the 2026 bear market as its supply in loss hits 45% on Wednesday, March 11. The midterm bearish outlook for Bitcoin has been ...

Regeneron’s Chinese partner reported Zepbound-like efficacy in a phase 3 trial, de-risking one part of the Big Biotech’s differentiated play for the obesity market. New York-based Regeneron made a ...